Factor XIII Deficiency: Laboratory, Molecular, and Clinical Aspects

Area of Science:

• Hematology
• Rare bleeding disorders
• Coagulation factor deficiencies

Background:

• Factor XIII-A (FXIII-A) deficiency is a rare bleeding disorder with high morbidity, often due to intracranial hemorrhage, umbilical bleeding, and miscarriage.
• Severe FXIII-B deficiency has a milder phenotype, while heterozygous FXIII-A deficiency affects 0.8-3.5% and poses risks during hemostatic challenges, particularly for women.
• Over 200 mutations in F13A and F13B genes exist, mostly missense, with limited genotype-phenotype correlation but a link between factor activity and clinical severity.

Purpose of the Study:

• To review the clinical presentation, genetic basis, and therapeutic strategies for Factor XIII deficiency.
• To highlight the challenges in predicting bleeding patterns and the need for tailored treatment approaches.
• To emphasize the importance of personalized, pharmacokinetic-based replacement therapy for optimizing treatment efficacy.

Main Methods:

• Review of existing literature on Factor XIII deficiency.
• Analysis of genotype-phenotype correlations and factor activity levels.
• Evaluation of current therapeutic regimens and the rationale for personalized therapy.

Main Results:

• Severe FXIII-A deficiency requires primary prophylaxis; heterozygous FXIII-A deficiency and FXIII-B deficiency often necessitate on-demand therapy, especially for women with FXIII-A deficiency during hemostatic challenges.
• Genotype does not reliably predict phenotype, but factor activity correlates with clinical severity.
• Personalized pharmacokinetic-based replacement therapy, considering various patient-specific factors, is the optimal treatment strategy.

Conclusions:

• Factor XIII deficiency management requires careful consideration of deficiency type, severity, and individual patient characteristics.
• Personalized therapy optimizes treatment efficacy for Factor XIII deficiency, moving beyond general guidelines.
• Further research into optimizing pharmacokinetic-based regimens can improve outcomes for patients with FXIII deficiency.